Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QFD2
|
|||
| Drug Name |
Upifitamab rilsodotin
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Company |
Mersana Therapeutics Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/phosphate cotransporter 2B (SLC34A2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05329545) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Mersana Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.